USE OF ANABOLIC HORMONE THERAPIES IN SARCOPENIA IN OLDER ADULTS: CURRENT EVIDENCE AND PROGNOSIS
DOI:
https://doi.org/10.56238/levv17n60-006Keywords:
Sarcopenia, Hormone Therapy, Testosterone, Aging, Skeletal MuscleAbstract
Sarcopenia is a multifactorial condition associated with aging, characterized by the progressive loss of skeletal muscle mass and function, with significant impact on physical performance and quality of life in older adults. In this context, anabolic hormone therapies have been investigated as potential strategies to mitigate this process. This study aimed to critically analyze the current scientific evidence regarding the use of these therapies in the management of sarcopenia in older individuals. This is a narrative literature review conducted using PubMed, ScienceDirect, and SciELO databases, including publications from 2016 to 2026. A total of 17 studies were selected, addressing testosterone replacement therapy (TRT), selective androgen receptor modulators (SARMs), and other hormonal approaches. The findings indicate that TRT consistently improves lean body mass and body composition; however, its effects on physical function remain heterogeneous. SARMs show promising anabolic effects in experimental models, but clinical evidence is still limited. Additionally, relevant concerns persist regarding the safety of these interventions, particularly in relation to cardiovascular risk and long-term outcomes. In conclusion, despite favorable effects on structural parameters, anabolic hormone therapies do not yet have sufficient evidence to support their use as standard treatment for sarcopenia, highlighting the need for further studies focusing on functional outcomes and long-term safety.
Downloads
References
AMANO, T. Late-onset hypogonadism: current methods of clinical management. 2025. DOI: https://doi.org/10.4103/aja2024111
BATSIS, J. A.; VILLAREAL, D. T. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology, v. 14, n. 9, p. 513–537, 2018. DOI: https://doi.org/10.1038/s41574-018-0062-9 DOI: https://doi.org/10.1038/s41574-018-0062-9
BHASIN, S. et al. Androgens and selective androgen receptor modulators to treat functional limitations associated with aging and chronic disease. The Journals of Gerontology: Series A, v. 78, supl. 1, p. S25–S31, 2023. DOI: https://doi.org/10.1093/gerona/glad027 DOI: https://doi.org/10.1093/gerona/glad027
BORECKI, R. et al. Selective androgen receptor modulators (SARMs) — potential anabolic drugs for the treatment of cachexia and frailty syndrome. Endokrynologia Polska, v. 76, n. 3, 2025. DOI: https://doi.org/10.5603/EP.104795 DOI: https://doi.org/10.5603/ep.104795
CHO, M. et al. A review of sarcopenia: pathophysiology, diagnosis and treatment. 2022. DOI: https://doi.org/10.3346/jkms.2022.37.e146
CHO, Y. Prevention and treatment of sarcopenia in diabetes. Journal of Korean Diabetes, v. 26, n. 2, p. 90–96, 2025. DOI: https://doi.org/10.4093/jkd.2025.26.2.90 DOI: https://doi.org/10.4093/jkd.2025.26.2.90
CHRISTIANSEN, A. R. et al. Selective androgen receptor modulators: the future of androgen therapy? Translational Andrology and Urology, v. 9, supl. 2, p. S135–S148, 2020. DOI: http://dx.doi.org/10.21037/tau.2019.11.02 DOI: https://doi.org/10.21037/tau.2019.11.02
HUANG, L.-T.; WANG, J.-H. The therapeutic intervention of sex steroid hormones for sarcopenia. Frontiers in Medicine, v. 8, 2021. DOI: https://doi.org/10.3389/fmed.2021.739251 DOI: https://doi.org/10.3389/fmed.2021.739251
KHODAMORADI, K. et al. Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects. Fertility and Sterility Reports, v. 2, n. 1, p. 32–42, 2021. DOI: https://doi.org/10.1016/j.xfre.2020.10.013 DOI: https://doi.org/10.1016/j.xfnr.2020.11.001
KILGORE, C. Exercise may be best remedy for sarcopenia. Caring for the Ages, v. 17, n. 5, 2016. DOI: https://doi.org/10.1016/j.carage.2016.04.001
MINNETTI, M. et al. Endocrinological aspects of sarcopenic obesity. Annals of Medicine, v. 58, n. 1, 2026. DOI: https://doi.org/10.1080/07853890.2026.2626085 DOI: https://doi.org/10.1080/07853890.2026.2626085
MORIMOTO, M. et al. A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels. Pharmacology Research & Perspectives, v. 8, n. 1, 2020. DOI: https://doi.org/10.1002/prp2.563 DOI: https://doi.org/10.1002/prp2.563
NIGHTINGALE, T. E. et al. Body composition changes with testosterone replacement therapy following spinal cord injury and aging: a mini review. The Journal of Spinal Cord Medicine, v. 41, n. 6, p. 624–634, 2018. DOI: https://doi.org/10.1080/10790268.2017.1357917 DOI: https://doi.org/10.1080/10790268.2017.1357917
SHIN, M. J.; JEON, Y. K.; KIM, I. J. Testosterone and sarcopenia. World Journal of Men’s Health, v. 36, n. 3, p. 192–198, 2018. DOI: https://doi.org/10.5534/wjmh.180001 DOI: https://doi.org/10.5534/wjmh.180001
SPRINGER, J.; SPRINGER, J.-I.; ANKER, S. D. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Failure, v. 4, n. 4, p. 492–498, 2017. DOI: https://doi.org/10.1002/ehf2.12202 DOI: https://doi.org/10.1002/ehf2.12237
TAKAYAMA, K. The biological and clinical advances of androgen receptor function. 2017. DOI: https://doi.org/10.1507/endocrj.EJ17-0328
WANG, C.; SWERDLOFF, R. S. Testosterone replacement therapy in hypogonadal men. Endocrinology and Metabolism Clinics of North America, v. 51, n. 1, p. 77–98, 2022. DOI: https://doi.org/10.1016/j.ecl.2021.11.005 DOI: https://doi.org/10.1016/j.ecl.2021.11.005
